Skip to main
COGT

Cogint (COGT) Stock Forecast & Price Target

Cogint (COGT) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 30%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Cogent Biosciences Inc. is positioned for significant milestones in 2025, which may enhance its attractiveness as a potential acquisition target, contingent on positive outcomes from the APEX and PEAK trials. The SUMMIT trial results demonstrated substantial benefits, with a notable 87.4% of patients treated with bezuclastinib experiencing a reduction of serum tryptase, indicating its therapeutic effectiveness. Furthermore, the adjustments to the discounted cash flow (DCF) valuation reflect confidence in a 90% probability of approval for bezuclastinib in treating gastrointestinal stromal tumors, alongside a raised peak penetration rate, showcasing the stock's positive outlook in the biotechnology sector.

Bears say

Cogent Biosciences faces several significant risks that contribute to a negative financial outlook, including potential negative clinical data for its drug bezuclastinib and slower-than-expected development timelines. The company has recorded growing net losses, including a net loss of $80.9 million in the third quarter of 2025, which exceeded prior estimates. Additionally, the projected full-year 2025 net loss per share is anticipated to be $2.39, highlighting ongoing financial challenges and concerns regarding the company's commercial success and potential dilution of shareholder value.

Cogint (COGT) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 30% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cogint and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cogint (COGT) Forecast

Analysts have given Cogint (COGT) a Buy based on their latest research and market trends.

According to 10 analysts, Cogint (COGT) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cogint (COGT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.